These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 2499263)

  • 61. Generation of monoclonal antibodies reacting with human epithelial ovarian cancer.
    Tagliabue E; Mènard S; Della Torre G; Barbanti P; Mariani-Costantini R; Porro G; Colnaghi MI
    Cancer Res; 1985 Jan; 45(1):379-85. PubMed ID: 3965146
    [TBL] [Abstract][Full Text] [Related]  

  • 62. [A study of the T-antigen in ovarian tumor].
    Tenjin H
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Jan; 42(1):30-6. PubMed ID: 2153744
    [TBL] [Abstract][Full Text] [Related]  

  • 63. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).
    Nozawa S; Yajima M; Sasaki H; Tsukazaki K; Aoki D; Sakayori M; Udagawa Y; Kobayashi T; Sato I; Furusako S
    Jpn J Cancer Res; 1991 Jul; 82(7):854-61. PubMed ID: 1715339
    [TBL] [Abstract][Full Text] [Related]  

  • 64. [Applications of tumor markers to the screening of endometrial and ovarian cancers].
    Nozawa S; Takamatsu K; Tsukazaki K; Udagawa Y
    Nihon Rinsho; 1996 Jun; 54(6):1665-73. PubMed ID: 8691627
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Purification and characterisation of the placental-like alkaline phosphatase from ovarian epithelial tumours.
    Koyama I; Hirano K; Makiya R; Stendahl U; Stigbrand T
    Br J Cancer Suppl; 1990 Jul; 10():6-11. PubMed ID: 2383481
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Clinical significance of the tumour markers CA 125 II and CA 72-4 in ovarian carcinoma.
    Hasholzner U; Baumgartner L; Stieber P; Meier W; Reiter W; Pahl H; Fateh-Moghadam A
    Int J Cancer; 1996 Aug; 69(4):329-34. PubMed ID: 8797878
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.
    Kobayashi H; Ohi H; Fujii T; Terao T
    Br J Cancer; 1993 Feb; 67(2):237-43. PubMed ID: 7679280
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Establishment of hybridomas secreting monoclonal antibodies to placental alkaline phosphatase and development of an enzyme immunoassay for its determination.
    Kinoshita Y; Okamoto T; Mano H; Furuhashi Y; Goto S; Tomoda Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Jun; 42(6):613-9. PubMed ID: 2205681
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Expression of cell-mediated immunity and blocking factor using a new line of ovarian cancer cells in vitro.
    Pattillo RA; Story MT; Ruckert AC
    Cancer Res; 1979 Apr; 39(4):1185-92. PubMed ID: 421202
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [Biological properties of two newly established cell lines (RMUG-S, RMUG-L) from a human ovarian mucinous cystadenocarcinoma].
    Sakayori M; Nozawa S; Udagawa Y; Chin K; Lee SG; Sakuma T; Iizuka R; Wada Y; Yoshida S; Takeda Y
    Hum Cell; 1990 Mar; 3(1):52-6. PubMed ID: 2083224
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Tumor-associated antigen for cystadenocarcinomas of the ovary.
    Bhattacharya M; Barlow JJ
    Natl Cancer Inst Monogr; 1975 Oct; 42():25-32. PubMed ID: 825781
    [TBL] [Abstract][Full Text] [Related]  

  • 72. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
    Kobayashi H; Kawashima Y
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
    [TBL] [Abstract][Full Text] [Related]  

  • 73. CA125 and placental alkaline phosphatase as serum tumor markers in epithelial ovarian carcinoma.
    Vergote IB; Abeler VM; Børmer OP; Stigbrand T; Tropé C; Nustad K
    Tumour Biol; 1992; 13(3):168-74. PubMed ID: 1626181
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Placental alkaline phosphatase as a tumor marker in ovarian cancer.
    Vergote I; Onsrud M; Nustad K
    Obstet Gynecol; 1987 Feb; 69(2):228-32. PubMed ID: 3808507
    [TBL] [Abstract][Full Text] [Related]  

  • 75. An immunoenzymometric assay for a CA125-like antigen, CA602.
    Mochizuki H; Sato I; Nagoya K; Furusako S; Yamauchi T; Masuko H; Sato H; Morishita H; Yajima M; Sasaki H
    J Clin Lab Anal; 1992; 6(2):84-90. PubMed ID: 1383480
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Basic and clinical evaluation of an immunoradiometric competitive inhibition assay for sialyl TN antigen: (2). Evaluation of clinical significance. STN Study Group].
    Imura H; Mori T; Ohkura H; Ishii M; Ariyoshi H; Endo J; Kitao M; Takeda I; Kobayashi H; Inoue M
    Gan To Kagaku Ryoho; 1989 Sep; 16(9):3221-30. PubMed ID: 2571323
    [TBL] [Abstract][Full Text] [Related]  

  • 77. [Clinical usefulness of monoclonal antibody, CA 125 and CA 19-9 in ovarian cancer].
    Saitoh S; Nakanishi A; Noda T; Ando Y; Katakami Y; Kiyozuka Y; Moriyama I; Ichijo M
    Nihon Gan Chiryo Gakkai Shi; 1984 Dec; 19(10):2327-35. PubMed ID: 6598184
    [No Abstract]   [Full Text] [Related]  

  • 78. Ovarian tumor-specific antigens.
    Knauf S; Urbach GI
    Am J Obstet Gynecol; 1974 Aug; 119(7):966-70. PubMed ID: 4135399
    [No Abstract]   [Full Text] [Related]  

  • 79. Morphological and immunological heterogeneity of human ovarian neoplasms.
    Harłozińska A; Rabczyński J; Bar JK; Richter R
    Arch Immunol Ther Exp (Warsz); 1991; 39(4):419-29. PubMed ID: 1821619
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Coordinate elevation of serum markers in ovarian cancer but not in benign disease.
    Bast RC; Knauf S; Epenetos A; Dhokia B; Daly L; Tanner M; Soper J; Creasman W; Gall S; Knapp RC
    Cancer; 1991 Oct; 68(8):1758-63. PubMed ID: 1913520
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.